GlassScriptPhysician profile
Eric D Pauley
NPI 1689019457
$4,610.07
in general payments reported to CMS, 2019-2025
36 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $252 · 2021: $113 · 2022: $792 · 2023: $652 · 2024: $1,180 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $758.58 | 2019-2025 | Diamondback Coronary, Dragonfly Opstar, Xience Skypoint |
| Recor Medical INC | $552.74 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Cardiovascular Systems INC. | $382.39 | 2020-2023 | Diamondback Coronary |
| Boston Scientific Corporation | $338.47 | 2019-2025 | Rotablator Rotational Atherectomy System Console Kit, Synergy, Rotapro |
| E.R. Squibb & Sons, L.L.C. | $258.08 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $257.57 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $221.19 | 2022-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $220.75 | 2021-2025 | |
| Amgen INC. | $185.64 | 2022-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $126.60 | 2023-2025 | Onpattro |
| Medtronic, INC. | $102.83 | 2023 | Hawkone |
| Balt USA, LLC | $98.20 | 2022-2025 | Prestige Coil System |
| Astrazeneca Pharmaceuticals LP | $94.32 | 2022-2025 | Farxiga |
| Cardinal Health 200 LLC | $91.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $91.30 | 2022-2024 | Xarelto |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $76.06 | 2023-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.26 | 2023-2025 | Jardiance |
| Medtronic Vascular, INC. | $72.62 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.88 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.81 | 2022-2023 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $54.48 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $51.76 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $46.74 | 2024 | Arcalyst |
| Novo Nordisk INC | $44.69 | 2024 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $36.30 | 2023 | |
| W. L. Gore & Associates, INC. | $35.79 | 2022-2023 | Gore Viabil Biliary Endoprosthesis |
| Shockwave Medical, INC | $33.24 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kestra Medical Technology Services, INC. | $29.88 | 2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $25.64 | 2025 | Nexletol |
| Vital Connect, INC | $23.17 | 2023 | Vitalpatch Rtm |
| Actelion Pharmaceuticals US, INC. | $21.11 | 2024 | Opsumit |
| Lexicon Pharmaceuticals, INC. | $20.91 | 2023 | Inpefa |
| Cvrx, INC. | $18.61 | 2024 | Barostim Neo System |
| Bard Peripheral Vascular, INC. | $16.72 | 2020 | |
| Daiichi Sankyo INC. | $15.35 | 2025 | Injectafer |
| Chiesi USA, INC. | $13.59 | 2024 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Pauley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.